



# Temperature Mapping

Katie Corrigan

Health Products Distribution Inspector

---

**HPRA GDP Information Day**

3<sup>rd</sup> May 2022

Radisson Blu Royal Hotel, Dublin



## Temperature Mapping

- Examples of specific storage statements declared on the label of a medicinal product:
  - Do not store above 25°C/Do not store above 30°C
  - Store below 25°C/Store below 30°C
  - Store in a refrigerator (2°C – 8°C)
  - Store and transport refrigerated (2°C – 8°C)
  - Store in a freezer (temperature range)\*
  - Do not refrigerate/Do not freeze
  - (\*Freezer storage temperatures may vary from 0°C to -20°C or below -20°C)



## Deficiencies breakdown by frequency

Major Deficiency	Percentage frequency
Management of temperature at the site was deficient	87%
Mapping studies were not performed correctly or not at all	79%
CC/CAPA/Deviations raised not handled correctly or not raised/not fit for purpose	47%
Storage of medicinal products at the site was deficient	23%
Validation study and management of was deficient (transport)	20%



## Overview

- Temperature mapping through the distribution process
  - Systematic approach to conducting temperature mapping
  - Specific guidance for cold chain
  - Considerations for the transportation of medicinal products




## Requirement for Mapping Study?

- Risk assessment of area and location of temperature monitoring probes
- The use of a max/min thermometer should be employed as a means of continuous temperature monitoring



# Conducting a temperature mapping study





# Temperature Mapping – Protocol

Initial mapping

Mapping under representative conditions

Door Opening

Power outage



## Risk Assessment

- Identify areas of risk – example windows, doors, chillers or other equipment which may contribute to temperature fluctuations



© CanStockPhoto.com



shutterstock.com · 1254049606



alamy


Image © MACHO  
www.alamy.com






## Probes

- Temperature recording probes should have an accuracy of at least  $\pm 0.5^{\circ}\text{C}$ .
- The temperature monitoring devices should be calibrated on an annual basis against a certified, traceable reference standard.
- Calibrations should be performed for at least three points across the range of temperatures for which the probe will be used (e.g. 0, 15 and 30 °C for ambient warehouse probes; -10, 0, 10°C for refrigerator probes).
- Auxillary probes should be used during calibration process



## Perform Study!





## Deficiencies breakdown by frequency

Major Deficiency	Percentage frequency
<b>The management of temperature at the site was deficient</b>	87%
Mapping studies were not performed correctly or not at all	79%
CC/CAPA/Deviations raised not handled correctly or not raised/not fit for purpose	47%
The storage of medicinal products at the site was deficient	23%
Validation study and management of was deficient (transport)	20%



## Deficiencies breakdown by frequency

Major Deficiency	Percentage frequency
The management of temperature at the site was deficient	87%
<b>Mapping studies were not performed correctly or not at all</b>	79%
CC/CAPA/Deviations raised not handled correctly or not raised/not fit for purpose	47%
The storage of medicinal products at the site was deficient	23%
Validation study and management of was deficient (transport)	20%



## Results – Interrogation of findings

- At a minimum, identified area with the most extreme temperature fluctuations. (highest and lowest temperatures recorded)
- Justify the number and placement of the probes
- How will door opening & power outages be managed based on the findings



## Document results

- Location of permanent probe placements
- Set point of the alarms
- Set point of any equipment used



## Repetition of mapping studies

- Seasonal mapping studies
- Structural changes
- Set periodic frequency
- Action to be taken in event of a temperature excursion



## Deficiencies breakdown by frequency

Major Deficiency	Percentage frequency
<b>The management of temperature at the site was deficient</b>	87%
Mapping studies were not performed correctly or not at all	79%
CC/CAPA/Deviations raised not handled correctly or not raised/not fit for purpose	47%
The storage of medicinal products at the site was deficient	23%
Validation study and management of was deficient (transport)	20%





## Deficiencies breakdown by frequency

Major Deficiency	Percentage frequency
The management of temperature at the site was deficient	87%
<b>Mapping studies were not performed correctly or not at all</b>	79%
CC/CAPA/Deviations raised not handled correctly or not raised/not fit for purpose	47%
The storage of medicinal products at the site was deficient	23%
Validation study and management of was deficient (transport)	20%



## Deficiencies breakdown by frequency

Major Deficiency	Percentage frequency
The management of temperature at the site was deficient	87%
Mapping studies were not performed correctly or not at all	79%
<b>CC/CAPA/Deviations raised not handled correctly or not raised/not fit for purpose</b>	47%
The storage of medicinal products at the site was deficient	23%
Validation study and management of was deficient (transport)	20%




# Specific Guidance for Cold Chain

---



## Specific Guidance for cold chain mapping

- Spacing/Occupancy of medicinal products within the fridge / freezer
- Storage in relation to chillers/air flow units
- Impact of door opening
- Dual systems – system A/system B units





# Transportation

---



# Transportation of medicinal products

## Active vs passive transport





# Passive Transport

Manufacturing  
Specifications

Door Opening

Conditioning  
times

Loading of  
product

Seasonal  
Impacts



## Summary

- Consider the environment and the impact it may have in parallel with proposed activity.
- Document the environmental settings at the time of the study
- Justify, justify & justify!
- Document findings
- Consider changes which may trigger the requirement to perform a remapping exercise





## Resources

- *HPRA Guide to Control and Monitoring of Storage and Transportation Temperature Conditions for Medicinal Products and Active Substances*
- *HPRA Guide to Good Distribution Practice of Medicinal Products for Human Use*
- *Chapter 3, EU GDP Guidelines of medicinal products for human use, 2013/C 343/01*
- *Chapter 5, EU GDP Guidelines of active substances for medicinal products for human use 2015/C 95/01*



# Thank you

---